The second batch of Commissioner's national priority vouchers (CNPVs) has been published by the FDA, and includes new GLP-1 agonists for weight-loss from Eli Lilly and Novo Nordisk and drugs for ...
The FDA has lost no time in approving the first drug under its recently launched Commissioner's National Priority Voucher (CNPV) programme, clearing an antibiotic manufactured in the US. The fast ...
Morningstar analysts do not currently cover PRIFpD, but with our powerful screener, you can find stocks in the same sector,industry, or style and filter on our unbiased ratings and valuation metrics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback